News & Updates
Filter by Specialty:
Nicorandil improves PCI outcomes in STEMI patients
In patients with ST‐segment–elevation myocardial infarction (STEMI), treatment with nicorandil prior to undergoing primary percutaneous coronary intervention (PCI) may result in improved myocardial perfusion grade, increased left ventricular ejection fraction, and reduced myocardial infarct size, according to data from the CHANGE* study.
Nicorandil improves PCI outcomes in STEMI patients
14 Sep 2022
Ivermectin not superior to placebo in mild COVID-19
Early treatment with single- or double-dose ivermectin is no better than placebo in avoiding progression to hospitalization and in improving symptoms in mild COVID-19, results of a study have shown.
Ivermectin not superior to placebo in mild COVID-19
13 Sep 2022
Nirmatrelvir conferred protection in older adults during the Omicron outbreak
During the surge of the Omicron (B.1.1.529) variant, antiviral therapy with nirmatrelvir significantly reduced the rate of COVID-19-related hospitalization or death among patients aged ≥65 years, according to a recent study.
Nirmatrelvir conferred protection in older adults during the Omicron outbreak
13 Sep 2022
Polypill strategy triumphs in reducing MACE post-MI
A polypill comprising aspirin, ramipril, and atorvastatin, significantly reduced the incidence of major adverse cardiovascular (CV) events in patents with a recent myocardial infarction (MI), according to results of a phase III trial presented at ESC 2022.
Polypill strategy triumphs in reducing MACE post-MI
12 Sep 2022
Patients upset by frequent side effects of RA drugs
Symptomatic adverse events (AEs) are common and troublesome for many patients with rheumatoid arthritis (RA) who are taking medications for their condition, results of an exploratory study have shown.
